IRCCS Istituto tumori Giovanni Paolo II
About IRCCS Istituto tumori Giovanni Paolo II
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
22
Incyte Corporation
9
Consorzio Oncotech
4
Fondazione Ricerca Traslazionale
4
Fondazione Italiana Linfomi ONLUS
3
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
3
Italian Sarcoma Group
3
Loxo Oncology, Inc.
3
Mario Negri Institute for Pharmacological Research
3
Pfizer
3
Canadian Cancer Trials Group
2
Clinical Trials at IRCCS Istituto tumori Giovanni Paolo II
During the past decade, IRCCS Istituto tumori Giovanni Paolo II conducted 64 clinical trials. In the 10-year time frame, 64 clinical trials started and 24 clinical trials were completed, i.e. on
average, 37.5% percent of trials that started reached the finish line to date. In the past 5 years, 27 clinical trials started and 11 clinical trials were completed. i.e. 40.7%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Docetaxel in Treating Patients With Non-Small Cell Lung Cancer
2000-12-01
Unknown status
200
Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer
2001-09-01
Unknown status
700
A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma
2007-07-26
2011-11-30
Terminated
787
Multicentric Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Patients With Stage II-IV Follicular Lymphoma
2005-12-01
2014-03-01
Unknown status
534
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
2009-04-23
2014-02-12
Completed
529
Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma
2007-10-01
2012-01-01
Unknown status
49
Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
2008-03-01
2014-12-01
Completed
320
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
2011-01-13
2016-11-30
Completed
343
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "IRCCS Istituto tumori Giovanni Paolo II" #1 sponsor was "Hoffmann-La Roche" with 22 trials, followed by "Incyte Corporation" with 9 trials
sponsored, "Consorzio Oncotech" with 4 trials sponsored, "Fondazione Ricerca Traslazionale" with 4 trials sponsored and "Fondazione Italiana Linfomi ONLUS"
with 4 trials sponsored. Other sponsors include 47 different institutions and
companies that sponsored additional 43 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "IRCCS Istituto tumori Giovanni Paolo II"
#1 collaborator was "Merck Sharp & Dohme LLC" with 4 trials as a collaborator, "Bristol-Myers Squibb" with 3 trials as a collaborator, "Eli Lilly and Company" with 3 trials as a collaborator, "Clinical Research Technology S.r.l." with 2 trials as a collaborator and "Hoffmann-La Roche" with 2 trials as a collaborator. Other collaborators include 41 different institutions and companies that were
collaborators in the rest 49 trials.
Clinical Trials Conditions at IRCCS Istituto tumori Giovanni Paolo II
According to Clinical.Site data, the most researched conditions in "IRCCS Istituto tumori Giovanni Paolo II" are
"Melanoma" (5 trials), "Carcinoma, Non-Small-Cell Lung" (4 trials), "Follicular Lymphoma" (4 trials), "Malignant Melanoma" (4 trials) and "Breast Cancer" (3 trials). Many other conditions were trialed in "IRCCS Istituto tumori Giovanni Paolo II" in a lesser frequency.
Clinical Trials Intervention Types at IRCCS Istituto tumori Giovanni Paolo II
Most popular intervention types in "IRCCS Istituto tumori Giovanni Paolo II" are "Drug" (78 trials), "Biological" (6 trials), "Other" (5 trials), "Procedure" (5 trials) and "Radiation" (2 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (10 trials), "Rituximab" (7 trials), "Atezolizumab" (6 trials), "Carboplatin" (6 trials) and "Pembrolizumab" (6 trials). Other intervention names were less common.
Clinical Trials Genders at IRCCS Istituto tumori Giovanni Paolo II
The vast majority of trials in "IRCCS Istituto tumori Giovanni Paolo II" are
86 trials for "All" genders, 7 trials for "Female" genders and 1 trials for "Male" genders.
Clinical Trials Status at IRCCS Istituto tumori Giovanni Paolo II
Currently, there are NaN active trials in "IRCCS Istituto tumori Giovanni Paolo II".
1 are not yet recruiting,
23 are recruiting,
22 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 27 completed trials in IRCCS Istituto tumori Giovanni Paolo II,
undefined suspended trials,
and 7 terminated clinical trials to date.
Out of the total trials that were conducted in IRCCS Istituto tumori Giovanni Paolo II, 1 "Phase 1"
clinical trials were conducted, 29 "Phase 2" clinical
trials and 51 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 1 trials, and there were
also 1 trials that are defined as “Not Applicable".